- Applied DNA Sciences to Begin Trading Under New Ticker ‘BNBX' Reflecting Digital Asset Treasury Strategy
Oct 6, 2025 · businesswire.com
STONY BROOK, N.Y.--(BUSINESS WIRE)--Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a biotechnology company advancing a yield focused BNB digital asset treasury strategy and commercializing nucleic acid production solutions, today announced that it will change its ticker symbol on the Nasdaq Capital Market (“Nasdaq”) from “APDN” to “BNBX”, effective at the opening of trading on Tuesday October 7, 2025. The ticker BNBX underscores the Company's strategic commitment to.
- APPLIED DNA SCIENCES TO BEGIN TRADING UNDER NEW TICKER ‘BNBX' REFLECTING DIGITAL ASSET TREASURY STRATEGY
Oct 6, 2025
STONY BROOK, N.Y.--(BUSINESS WIRE)--APPLIED DNA SCIENCES, INC. (NASDAQ: APDN) (“APPLIED DNA” OR THE “COMPANY”), A BIOTECHNOLOGY COMPANY ADVANCING A YIELD FOCUSED BNB DIGITAL ASSET TREASURY STRATEGY AND COMMERCIALIZING NUCLEIC ACID PRODUCTION SOLUTIONS, TODAY ANNOUNCED THAT IT WILL CHANGE ITS TICKER SYMBOL ON THE NASDAQ CAPITAL MARKET (“NASDAQ”) FROM “APDN” TO “BNBX”, EFFECTIVE AT THE OPENING OF TRADING ON TUESDAY OCTOBER 7, 2025. THE TICKER BNBX UNDERSCORES THE COMPANY'S STRATEGIC COMMITMENT TO.
- Applied DNA Sciences Announces Private Placement of Up To $58 Million To Initiate BNB Treasury Strategy and BNB Native Yield Generation
Sep 29, 2025 · businesswire.com
STONY BROOK, N.Y.--(BUSINESS WIRE)--Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a biotechnology company focused on providing nucleic acid production solutions, today announced up to $58 million in commitments for a private investment in public equity (“PIPE”) offering led by institutional investors to initiate a digital asset treasury strategy based on BNB, the native cryptocurrency of the Binance blockchain ecosystem, the world's largest cryptocurrency exchange1.
- APPLIED DNA SCIENCES ANNOUNCES PRIVATE PLACEMENT OF UP TO $58 MILLION TO INITIATE BNB TREASURY STRATEGY AND BNB NATIVE YIELD GENERATION
Sep 29, 2025
STONY BROOK, N.Y.--(BUSINESS WIRE)--APPLIED DNA SCIENCES, INC. (NASDAQ: APDN) (“APPLIED DNA” OR THE “COMPANY”), A BIOTECHNOLOGY COMPANY FOCUSED ON PROVIDING NUCLEIC ACID PRODUCTION SOLUTIONS, TODAY ANNOUNCED UP TO $58 MILLION IN COMMITMENTS FOR A PRIVATE INVESTMENT IN PUBLIC EQUITY (“PIPE”) OFFERING LED BY INSTITUTIONAL INVESTORS TO INITIATE A DIGITAL ASSET TREASURY STRATEGY BASED ON BNB, THE NATIVE CRYPTOCURRENCY OF THE BINANCE BLOCKCHAIN ECOSYSTEM, THE WORLD'S LARGEST CRYPTOCURRENCY EXCHANGE1.
- Applied DNA Abstracts Selected for Poster Presentations Showcasing LineaDNA and LineaIVT Platforms at Upcoming mRNA and CAR T Industry Conferences
Sep 23, 2025 · accessnewswire.com
STONY BROOK, NY / ACCESS Newswire / September 23, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a biotechnology company focused on providing nucleic acid production solutions for the biopharmaceutical and diagnostics industries, announced that members of its business development and technical teams will be in attendance at upcoming industry conferences and present posters that underscore the Company's flexible nucleic acid production solutions designed to meet critical unmet needs for the manufacture of advanced biotherapeutics: 4th Annual mRNA Process Development and CMC Summit (Boston, September 23-25) Title: Fast-tracking mRNA Medicines: a synthetic DNA platform to optimize mRNA production Authors: Atsuko Sangria1, Aaron Chung2, and Yuhua Sun2 Poster session date/time: Wednesday, September 24, at 3:10 p.m. Eastern Poster: link Also at the mRNA conference, Applied DNA will feature its IVT Discovery Kit, a powerful platform for evaluating and optimizing in vitro transcription (IVT).
- APPLIED DNA ABSTRACTS SELECTED FOR POSTER PRESENTATIONS SHOWCASING LINEADNA AND LINEAIVT PLATFORMS AT UPCOMING MRNA AND CAR T INDUSTRY CONFERENCES
Sep 23, 2025
STONY BROOK, NY / ACCESS NEWSWIRE / SEPTEMBER 23, 2025 / APPLIED DNA SCIENCES, INC. (NASDAQ:APDN) ("APPLIED DNA" OR THE "COMPANY"), A BIOTECHNOLOGY COMPANY FOCUSED ON PROVIDING NUCLEIC ACID PRODUCTION SOLUTIONS FOR THE BIOPHARMACEUTICAL AND DIAGNOSTICS INDUSTRIES, ANNOUNCED THAT MEMBERS OF ITS BUSINESS DEVELOPMENT AND TECHNICAL TEAMS WILL BE IN ATTENDANCE AT UPCOMING INDUSTRY CONFERENCES AND PRESENT POSTERS THAT UNDERSCORE THE COMPANY'S FLEXIBLE NUCLEIC ACID PRODUCTION SOLUTIONS DESIGNED TO MEET CRITICAL UNMET NEEDS FOR THE MANUFACTURE OF ADVANCED BIOTHERAPEUTICS: 4TH ANNUAL MRNA PROCESS DEVELOPMENT AND CMC SUMMIT (BOSTON, SEPTEMBER 23-25) TITLE: FAST-TRACKING MRNA MEDICINES: A SYNTHETIC DNA PLATFORM TO OPTIMIZE MRNA PRODUCTION AUTHORS: ATSUKO SANGRIA1, AARON CHUNG2, AND YUHUA SUN2 POSTER SESSION DATE/TIME: WEDNESDAY, SEPTEMBER 24, AT 3:10 P.M. EASTERN POSTER: LINK ALSO AT THE MRNA CONFERENCE, APPLIED DNA WILL FEATURE ITS IVT DISCOVERY KIT, A POWERFUL PLATFORM FOR EVALUATING AND OPTIMIZING IN VITRO TRANSCRIPTION (IVT).
- Mpox in Africa is no longer a global health emergency, WHO chief says
Sep 6, 2025
[Blood collection tubes Mpox test positive results,WHO to rename monkeypox as ‘Mpox’]
JUN LI
The mpox outbreak that originated from Africa last year can no longer be considered a global emergency due to a sustained decline in cases and improved public health efforts, WHO Director-General Tedros Adhanom Ghebreyesus said on Friday.
In a press conference, Dr. Ghebreyesus said that he was lifting the declaration consistent with the recommendation of experts in WHO’s Mpox Emergency Committee, which had convened on Thursday.
In August 2024, the emergency committee of the U.N. agency declared the outbreak a public health emergency of international concern (PHEIC) in a bid to mobilize additional resources and run extensive public awareness campaigns, among other measures. [https://seekingalpha.com/news/4139935-who-declares-mpox-in-africa-is-a-global-health-emergency]
The classification, WHO’s highest level of warning, came after a newer and deadlier mpox variant emerged in early 2024 from Congo and later spread to neighboring countries, leading the Africa CDC, the region's top public health body, to declare the outbreak a continental emergency.
“I have accepted that advice,” he added, noting that “this decision is based on sustained declines in cases, as in the Democratic Republic of Congo, and in other affected countries, including Burundi, Sierra Leone, and Uganda.”
Dr. Ghebreyesus said that “lifting the emergency declaration does not mean the threat is over, nor that our response will stop,” adding that Africa CDC has decided [https://healthpolicy-watch.news/who-ends-international-emergency-declaration-for-mpox-but-vigilance-still-needed/] to stick to its regional emergency declaration during a meeting on Thursday.
Vaccine developers for monkeypox include Bavarian Nordic (OTCPK:BVNKF [https://seekingalpha.com/symbol/BVNKF]) (OTCPK:BVNRY [https://seekingalpha.com/symbol/BVNRY]) and Emergent BioSolutions (NYSE:EBS [https://seekingalpha.com/symbol/EBS]).
Developers of therapeutics for monkeypox: GeoVax Labs (GOVX [https://seekingalpha.com/symbol/GOVX]), SIGA Technologies (SIGA [https://seekingalpha.com/symbol/SIGA]), Chimerix (CMRX) and Tonix Pharmaceuticals (NASDAQ:TNXP [https://seekingalpha.com/symbol/TNXP]).
Monkeypox test makers: Co-Diagnostics (CODX [https://seekingalpha.com/symbol/CODX]), Roche (OTCQX:RHHBY [https://seekingalpha.com/symbol/RHHBY]) (OTCQX:RHHBF [https://seekingalpha.com/symbol/RHHBF]), Abbott Laboratories (NYSE:ABT [https://seekingalpha.com/symbol/ABT]), Applied DNA Sciences (APDN [https://seekingalpha.com/symbol/APDN])
MORE ON BAVARIAN NORDIC, ABBOTT, ETC.
* Bavarian Nordic A/S 2025 Q2 - Results - Earnings Call Presentation [https://seekingalpha.com/article/4816097-bavarian-nordic-a-s-2025-q2-results-earnings-call-presentation]
* Bavarian Nordic A/S (BVNKF) Q2 2025 Earnings Call Transcript [https://seekingalpha.com/article/4816095-bavarian-nordic-a-s-bvnkf-q2-2025-earnings-call-transcript]
* Tonix Pharmaceuticals Soars, Then Sinks: What's Next After Tonmya's Approval (Upgrade) [https://seekingalpha.com/article/4814864-tonix-pharma-soars-then-sinks-whats-next-after-tonmya-approval-upgrade]
* Medtronic wins FDA nod to integrate Abbott’s Instinct sensor with MiniMed 780G [https://seekingalpha.com/news/4491319-medtronic-wins-fda-nod-integrate-abbotts-instinct-sensor]
* Emergent Biosolutions awarded $30 million contract modification for CYFENDUS [https://seekingalpha.com/news/4491048-emergent-biosolutions-awarded-30-million-contract-modification-for-cyfendus]
- Applied DNA Sciences GAAP EPS of -$34, revenue of $304.39M
Aug 14, 2025
* Applied DNA Sciences press release [https://seekingalpha.com/pr/20201942-applied-dna-reports-third-quarter-fiscal-2025-financial-results] (NASDAQ:APDN [https://seekingalpha.com/symbol/APDN]): Q3 GAAP EPS of -$34
* Revenue of $304.39M.
MORE ON APPLIED DNA SCIENCES
* Applied DNA Sciences regains Nasdaq compliance [https://seekingalpha.com/news/4465602-applied-dna-sciences-regains-nasdaq-compliance]
* Applied DNA Sciences to focus solely on synthetic DNA, cuts 27% of staff [https://seekingalpha.com/news/4463729-applied-dna-sciences-to-focus-solely-on-synthetic-dna-cuts-27-of-staff]
* Seeking Alpha’s Quant Rating on Applied DNA Sciences [https://seekingalpha.com/symbol/APDN/ratings/quant-ratings]
* Historical earnings data for Applied DNA Sciences [https://seekingalpha.com/symbol/APDN/earnings]
* Financial information for Applied DNA Sciences [https://seekingalpha.com/symbol/APDN/income-statement]
- Applied DNA Reports Third Quarter Fiscal 2025 Financial Results
Aug 14, 2025 · accessnewswire.com
STONY BROOK, NY / ACCESS Newswire / August 14, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a biotechnology company focused on providing nucleic acid production solutions for the biopharmaceutical and diagnostics industries, today reported financial results for its third quarter of fiscal 2025 ended June 30, 2025. The Company's Form 10-Q for its fiscal third quarter can be viewed on the SEC Filings page of its Investor Relations website.
- APPLIED DNA REPORTS THIRD QUARTER FISCAL 2025 FINANCIAL RESULTS
Aug 14, 2025
STONY BROOK, NY / ACCESS NEWSWIRE / AUGUST 14, 2025 / APPLIED DNA SCIENCES, INC. (NASDAQ:APDN) ("APPLIED DNA" OR THE "COMPANY"), A BIOTECHNOLOGY COMPANY FOCUSED ON PROVIDING NUCLEIC ACID PRODUCTION SOLUTIONS FOR THE BIOPHARMACEUTICAL AND DIAGNOSTICS INDUSTRIES, TODAY REPORTED FINANCIAL RESULTS FOR ITS THIRD QUARTER OF FISCAL 2025 ENDED JUNE 30, 2025. THE COMPANY'S FORM 10-Q FOR ITS FISCAL THIRD QUARTER CAN BE VIEWED ON THE SEC FILINGS PAGE OF ITS INVESTOR RELATIONS WEBSITE.
